EP1043994A4 - Therapie der multiplen sklerose - Google Patents

Therapie der multiplen sklerose

Info

Publication number
EP1043994A4
EP1043994A4 EP99900751A EP99900751A EP1043994A4 EP 1043994 A4 EP1043994 A4 EP 1043994A4 EP 99900751 A EP99900751 A EP 99900751A EP 99900751 A EP99900751 A EP 99900751A EP 1043994 A4 EP1043994 A4 EP 1043994A4
Authority
EP
European Patent Office
Prior art keywords
multiple sclerosis
treating multiple
treating
sclerosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99900751A
Other languages
English (en)
French (fr)
Other versions
EP1043994A1 (de
Inventor
Siegfried B Christensen Iv
Theodore Torphy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1043994A1 publication Critical patent/EP1043994A1/de
Publication of EP1043994A4 publication Critical patent/EP1043994A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP99900751A 1998-01-07 1999-01-06 Therapie der multiplen sklerose Withdrawn EP1043994A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7067698P 1998-01-07 1998-01-07
US70676P 1998-01-07
PCT/US1999/000126 WO1999034797A1 (en) 1998-01-07 1999-01-06 Method for treating multiple sclerosis

Publications (2)

Publication Number Publication Date
EP1043994A1 EP1043994A1 (de) 2000-10-18
EP1043994A4 true EP1043994A4 (de) 2002-09-11

Family

ID=22096730

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99900751A Withdrawn EP1043994A4 (de) 1998-01-07 1999-01-06 Therapie der multiplen sklerose

Country Status (5)

Country Link
EP (1) EP1043994A4 (de)
JP (1) JP2002500187A (de)
AU (1) AU2026299A (de)
CA (1) CA2317548A1 (de)
WO (1) WO1999034797A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2258689A1 (de) 2000-03-16 2010-12-08 Biolipox AB Benzylierte PDE4-Inhibitoren
EP1893583B1 (de) 2005-05-31 2012-04-04 Pfizer Inc. Substituierte aryloxy-n-bicyclomethylacetamidverbindungen als vr1-antagonisten
MX2009012644A (es) 2007-06-05 2009-12-10 Sanofi Aventis Derivados de di(hetero)arilciclohexano, su preparacion, su uso y composiciones farmaceuticas que los comprenden.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019990A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552438A (en) * 1992-04-02 1996-09-03 Smithkline Beecham Corporation Compounds useful for treating allergic and inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996019990A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE MEDLINE [online] 1 August 1997 (1997-08-01), EKHOLM D ET AL: "Differential expression of cyclic nucleotide phosphodiesterase 3 and 4 activities in human T cell clones specific for myelin basic protein.", XP002205622, Database accession no. NLM9233651 *
DATABASE MEDLINE [online] October 1997 (1997-10-01), SOMMER N ET AL: "Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease.", XP002205623, Database accession no. NLM9357447 *
JOURNAL OF IMMUNOLOGY (BALTIMORE, MD.: 1950) UNITED STATES 1 AUG 1997, vol. 159, no. 3, 1 August 1997 (1997-08-01), pages 1520 - 1529, ISSN: 0022-1767 *
JOURNAL OF NEUROIMMUNOLOGY. NETHERLANDS OCT 1997, vol. 79, no. 1, October 1997 (1997-10-01), pages 54 - 61, ISSN: 0165-5728 *
See also references of WO9934797A1 *

Also Published As

Publication number Publication date
EP1043994A1 (de) 2000-10-18
JP2002500187A (ja) 2002-01-08
CA2317548A1 (en) 1999-07-15
WO1999034797A1 (en) 1999-07-15
AU2026299A (en) 1999-07-26

Similar Documents

Publication Publication Date Title
GB9809414D0 (en) Method
HK1039449A1 (zh) 治療多發性硬化的方法
GB9809776D0 (en) Method
GB0226147D0 (en) Treatment for multiple sclerosis
HUP9902097A3 (en) Method for treating glaucoma
EP1009403A4 (de) Verfahren zur behandlung von schizophrenie
EG23945A (en) Method for treating COPD
HUP9903779A3 (en) Method for treating amyotrophic lateral sclerosis
GB9810722D0 (en) Method
GB9819764D0 (en) Method
GB9814055D0 (en) Method
EP1043994A4 (de) Therapie der multiplen sklerose
GB9802475D0 (en) Method
GB9819769D0 (en) Method
GB9817266D0 (en) Method
GB9820185D0 (en) Method
GB9809782D0 (en) Method
GB9809780D0 (en) Method
GB9804355D0 (en) Method
SG77660A1 (en) Method for reducing alpha-aminoketone
SG77621A1 (en) Distribution method
GB9803648D0 (en) Method
GB9809293D0 (en) Method
GB9807810D0 (en) Method
GB9805450D0 (en) Method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20000731

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE CH DE ES FR GB IT LI NL

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/41 A, 7A 61K 31/235 B, 7A 61K 31/165 B, 7A 61K 31/075 B, 7A 61K 31/19 B, 7A 61K 31/215 B, 7A 61K 31/38 B, 7A 61K 31/425 B, 7A 61K 31/44 B, 7A 61K 31/505 B

A4 Supplementary search report drawn up and despatched

Effective date: 20020729

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): BE CH DE ES FR GB IT LI NL

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020801